NYU Langone Well being’s Perlmutter Most cancers Middle has named Jonathan M. Gerber, MD, as its new chief medical officer. Dr. Gerber joins NYU Langone from the College of Massachusetts Chan Medical College and UMass Memorial Well being, the place he served because the director of the most cancers heart and chief of hematology and oncology.
In his new position, Dr. Gerber will work with Perlmutter Most cancers Middle and NYU Langone management groups to ascertain and make sure the highest high quality of cutting-edge affected person care, efficient collaboration amongst college and employees, and the combination of medical and translational analysis at Perlmutter Most cancers Middle places all through Manhattan, Brooklyn, Queens, and Lengthy Island. He may also coordinate efforts throughout completely different most cancers specialties, departments, and campuses.
“I’m thrilled to be becoming a member of the Perlmutter Most cancers Middle because it continues to develop and evolve,” says Dr. Gerber. “I look ahead to working with colleagues throughout NYU Langone Well being to broaden and innovate the world-class care at every of our places.” He’s additionally a member of the Division of Hematology and Medical Oncology within the Division of Medication at NYU Grossman College of Medication.
Dr. Gerber’s medical pursuits embody leukemia and associated hematologic circumstances, in addition to blood and marrow transplantation (BMT) and mobile remedy. He’s additionally a translational laboratory researcher and an early-phase medical trial investigator. His analysis focuses on bettering the identification and focusing on of the stem cells on the root of leukemia and different hematologic illnesses, with the objective of personalizing remedy and growing therapies which might be more practical and fewer poisonous.
“Dr. Gerber is a confirmed chief on this planet of most cancers care and analysis,” says Alec Kimmelman, MD, PhD, the Anita Steckler and Joseph Steckler Chair of the Division of Radiation Oncology and director of the Perlmutter Most cancers Middle. “We’re lucky to have him be a part of our group to steer our medical efforts and to make sure all of our sufferers have entry to our excellent care and state-of-the-art medical trials.”
About Dr. Gerber
Dr. Gerber obtained his bachelor of arts in biology and medical diploma at Johns Hopkins, the place he additionally accomplished his inside drugs residency and hematology fellowship. Upon completion of his coaching, he served on the college of the Johns Hopkins College of Medication and Johns Hopkins Hospital for 5 years within the Division of Hematology. From there, he joined the Levine Most cancers Institute (LCI) because the founding director of its leukemia division. Whereas at LCI, he helped launch the BMT Program, performing the primary allogeneic BMT in an grownup in Charlotte, North Carolina, in 2014. In 2018, he was then recruited to be the chief of hematology and oncology and medical director of the most cancers service line on the College of Massachusetts Chan Medical College and UMass Memorial Well being, the place he was subsequently promoted to the director of the most cancers heart.
Dr. Gerber has co-authored over 50 articles in distinguished publications and has introduced analysis findings at nationwide and worldwide conferences, in addition to serving as a reviewer for the Nationwide Institutes of Well being and prime journals within the area. He’s additionally a member of the editorial board and the affiliate editor for hematology content material for HemOnc Immediately. Dr. Gerber was a member of the group that obtained a 2023 High 10 Scientific Analysis Achievement Award from the Scientific Analysis Discussion board for its work on the therapy of COVID-19 with convalescent plasma, which was revealed in The New England Journal of Medication. His leukemia analysis has resulted in three U.S. patents and has been translated into medical trials.
Dr. Gerber can also be an energetic member of a number of skilled societies, together with the American Society of Hematology (ASH) and the American Society of Scientific Oncology (ASCO). At the moment, he’s a member of the ASH Committee on Apply and the liaison to the ASH Subcommittee on Precision Medication, as a effectively as a member of the ASH Persevering with Certification Working Group. He beforehand served on the ASCO Most cancers Analysis and Schooling committees. Dr. Gerber has additionally served on the boards of the Charlotte and the New England chapters of the Leukemia & Lymphoma Society. As well as, he was a member of the Massachusetts Division of Public Well being’s Prognosis and Therapy Working Group for the 2024 to 2029 state most cancers plan.
Media Contact
Ryan Dziuba
Media Relations Supervisor
Ryan.Dziuba@NYULangone.org
212-404-4131
